590 results about "Hiv disease" patented technology

The invention belongs to the field of pharmaceutical and biological engineering, and relates to a CRISPR / Cas9 recombinant lentiviral vector for human immunodeficiency virus gene therapy and a lentivirus of the CRISPR / Cas9 recombinant lentiviral vector. The recombinant lentiviral vector is prepared by carrying out enzyme digestion on a lentiviral vectorlentiCRISPR by BsmBI and connecting into a BsmBI cohesive end-containing CXCR4 specific target sequence to recombine; the obtained CRISPR / Cas9 recombinant lentiviral vector is capable of mutating gene sequences at four different loci of ahuman immunodeficiency virusco-receptor CXCR4 and themutatuin rate is high and up to 25-75%. The cells transformed by the recombinant lentiviral vector cannot be infected by the human immunodeficiency virus. Compared with theRNAi-Knockdown, ZFN and TALEN technologies, the method has higher efficiency of suppressing the human immunodeficiency virus replication; the system is rapid to construct, simple and low in cost, is capable of preventing the invasion of the human immunodeficiency virus and is suitable for human immunodeficiency virus gene therapy.

The invention encompasses series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed

The invention belongs to the field of genetic engineering, and discloses a target sequence, recognized by a streptococcus thermophilus CRISPR-Cas9 system, of a human CCR5 gene, sgRNA and an application of the CRISPR-Cas9 system. The target sequence is shown as any one of the nth bit to the 30th bit of the SEQ ID NO:1-30, and n is equal to 1-12. The invention further relates to the sgRNA of the sequence -3' with the sequence of 5'-recognition sequence-recruiting Cas9 protein and a coded DNA molecule thereof. The DNA sequence corresponding to the recognition sequence is identical to the target sequence. The invention further relates to the CRISPR-Cas9 system. The system comprises Cas9 protein, the sgRNA and / or the coded sequence carrying the Cas9 protein and a carrier of the coded sequence of the sgRNA. The invention further relates to the application of the CRISPR-Cas9 system in editing the CCR5 gene and preparing medicine for HIV infection. Editing of the human CCR5 gene can be achieved, and therefore Aids is prevented and treated.

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: wherein: Z is Q is selected from the group consisting of: -W- is

The invention discloses sgRNA for specific targeting of a human CXCR4 gene, a sgRNA-containing staphylococcus aureus CRISPR / SaCas9 system and a method for specific human CXCR4 gene knockout by the method. A target sequence of sgRNA is shown as any one of SEQ ID NO:1-4. sgRNA for specific targeting of the human CXCR4 gene and AAV-CRISPR / SaCas9 plasmids are connected to form a carrier and packaged into AAV infection cells, simplicity, convenience, high efficiency and specificity in CXCR4 gene knockout are realized, and accordingly the problem of limitation in adoption of SpCas9 targeted CXCR4 for treatment of acquired immune deficiency syndrome is effectively solved.

The invention relates to a method for preparing plant extract from Chinese traditional medicine honeysuckle (Lonicera japonica Thunb.) or honeysuckle or other plants of same congenic strains, the honeysuckle extract and medical compound containing said extract. The effective component of said compound is secologanic acid and its derivants. The method comprises following steps: extracting with water or alcohol, depositing extract, refining through chromatogram, purifying with chromatogram if needed, getting extract with secologanic acid and its derivants concentration being more than 50%, or about 70% if better. The honeysuckle extract is characterized by analgesic, analgesic, analgesic, anti-biotic and antiviral function, and can be used to treat analgesic, pain, infectious disease, especially to treat atypical pneumonia, viral influenza and AIDS.

The present invention is related to nucleic acid sequences that can be used in the field of virus diagnostics, more specifically the diagnosis of infections with the AIDS causing Human Immuno-deficiency Virus (HIV).With the present invention nucleotide sequences are provided that can be used as primers and probes in the amplification and detection of HIV-1 nucleic acid. The oligonucleotide sequences provided with the present invention are located in the LTR part of the HIV viral genome. It has been found that, by using the sequences of the present invention in methods for the amplification and detection of nucleic acid a sensitive and specific detection of HIV-1 can be obtained. The benefit of the sequences of the present invention primarily resides in the fact that, with the aid of primers and probes comprising the sequences according to the invention the nucleic acid of all presently known subtypes of HIV-1 can be detected with high accuracy and sensitivity. So far no primer pairs or hybridization probes have been developed that would allow the detection of such a broad range of HIV-1 variants.The oligonucleotide sequences according to the present invention are especially useful in methods for the amplification of nucleic acid.

The invention relates to microchip-based assays to measure HIV-associated analytes of interest (e.g., CD4 lymphocytes, HIV RNA and liver enzymes) in a sample from a subject infected with the HIV virus. Methods of the present invention are optimal for use in monitoring HIV disease in resource-poor settings.

The invention discloses tenofovir diester compounds with activity of inhibiting HIV-1 (human immunodeficiency virus-1) virus replication and a preparation method and pharmaceutical use thereof. The structure of the compounds is shown in Formula (I), wherein m is 0-4, n is 12-16, and the structural formula is fixed when m is 1 and n is 14. The invention also discloses a preparation method of the compounds shown in the structural formula (I) and a pharmaceutical composition with the compounds. Tests show that the compounds have the activity of inhibiting HIV-1 replication and also much higher lipophilicity than the current HIV treatment drug tenofovir fumarate, and can be applied in development of drugs for treatment of HIV infection.

The invention discloses low molecular weight carboxyl-reduced derivatives of fucosylated glycosaminoglycans (LCRG). The extent of carboxyl reduction is not less than 20%. Weight-average molecular weight of the LCRG is about 3000-20000Da, and monosaccharides comprise acetyl galactosamine (GalNAc), glucose (Glc) or glucuronic acid (GlcUA) and fucose (Fuc) or sulfates of fucose (shown as -OSO3-). The mole ratio of GalNAc, Glc (containing GlcUA), Fuc and -OSO3- is about 1: (1+-0.3): (1+-0.3): (3.0+-1.0). The LCRG is a potent human immunodeficiency virus (HIV) Type 1 entry inhibitor which acts on conserved regions and has the advantages of high activity against HIV Type 1, high therapeutic index and no-drug-resistance, and the LCRG can be used for preventing or curing HIV. The invention further provides a preparation method of the LCRG. The carboxyl-reduced derivatives of fucosylated glycosaminoglycans and medicinal compositions of the carboxyl-reduced derivatives can be prepared into injection agents, lyophilized powder or suppository and the like.

The invention belongs to the field of antivirus in medical chemistry, and relates to preparation of non-cyclic nucleotide phosphoamides and salts thereof and application of the non-cyclic nucleotide phosphoamides and salts thereof in treating human immunodeficiency virus (HIV), hepatitis B, hepatitis B virus (HBV) and other virus infection diseases. The non-cyclic nucleotide phosphoamides, and isomers, pharmaceutically acceptable salts, hydrates, solvates or crystals thereof have the general formula I of which the structure is disclosed in the specification. The invention also provides a pharmaceutical composition containing the compounds and isomers, pharmaceutically acceptable salts, hydrates, solvates or crystals thereof, and application of the compounds or composition in treating and / or preventing HIV and HBV infection. The compounds provided by the invention have the advantages of favorable anti-HIV and HBV activities, low oral dosage and low toxicity.

The invention discloses a low molecular weight glycosylated chondroitin sulfate, whose weight average molecular weight is 3000-15000Da. The monosaccharide composition comprises acetyl galactosamine (D-GalNAc), glucuronic acid (D-GlcUA), fucose (L-Fuc), or its sulfuric ester (expressed in -OS03<->), wherein the mole ratio of D-GalNAc to D-GlcUA to L-Fuc to -OS03<-> is 1: (1+ / -0.3): (1+ / -0.3): (3.5+ / -0.5). The low molecular weight glycosylated chondroitin sulfate has a strong anti-HIV-1 virus activity, is a gp120 entry inhibitor, and can be used for preventing and / or treating AIDS. The invention also provides a method for preparing the low molecular weight glycosylated chondroitin sulfate and its composition preparation. Glycosylated chondroitin sulfate is depolymerized by the peroxide method to obtain a low molecular weight product, and then low molecular and / or high-molecular impurities of the product are removed by gel separation or ultrafiltration method. The low molecular weight glycosylated chondroitin sulfate and its medicinal composition can be prepared in the form of an injection, a lyophilized powder or a suppository.

The invention discloses 1H-indazole-4-amine compounds and further discloses a preparation method of the 1H-indazole-4-amine compounds and an application of the 1H-indazole-4-amine compounds as an IDO (indoleamine 2,3-dioxygenase) inhibitor. The 1H-indazole-4-amine compounds can be used for preventing and / or treating various diseases such as Alzheimer's disease, cataract, cellular immune activation associated infection, autoimmune disease, acquired immune deficiency syndrome, cancer, depression or tryptophan metabolic disorder.

The invention concerns agents for the treatment of acute and chronic infections with human and animal pathogenic viruses which assemble along the cell membrane and are released through budding on the surface of the cell. Hereunto count especially causative agents of infectious diseases such as AIDS, hepatitis, hemorrhagic fever, SARS, smallpox, measles, polio or the flu. The subjects of the invention are agents that contain inhibitors of the protein folding as active components. Hereunto count inhibitors of cellular folding enzymes (the enzymatic chaperones) as well as substances that disturb the folding of proteins through chemical chaperones. The following substance classes and their derivates belong thereunto: Geldanamycin, Deoxyspergualin, 4-PBA or Herbimycin A. Due to these agents the highly organised processes of the assembly and the proteolytical maturation of virus structure proteins is disturbed. As a result the release and production of infectious decendent viruses is prevented.

There are provided multimeric fusion proteins exhibiting anti-viral activity. The fusion proteins comprise the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein which is fused to a multimerisation domain peptide such as a trimerisation domain derived from tetranectin. The multimerised fusion proteins may be used as HIV fusion inhibitors in the treatment of AIDS.

The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and / or premature aging. The compounds of formula (Ia) being:where:R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group;R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; andR1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

The invention discloses a potential preparation method for a highly-efficient recombinant HIV-1 CRF07-BC gp140 immunogen. The immunogen is designed based on the structure of HIV-1 envelope protein crystals which have been published internationally and obtained in our lab. The specific method uses an overlap extension PCR technology to obtain gp140 gene segments, and comprises the steps that target genes are cloned into an eukaryotic expression vector pMT, endotoxin is removed through extraction of a large amount of plasmids, the gp140 gene segments and resistance screening plasmids pCoBlast are co-transfected into drosophila melanogaster Schneider2 (S2) cells together, blasticidin (Blasticidin S) is used for positive clone screening, S2 cell lines for stably and efficiently secreting and expressing gp140 are screened, and after enlarged cultivation and through two steps of purification of nickel column affinity chromatography and gel filtration chromatography, the gp140 with high purity can be obtained. A series of biochemical and biophysical technologies indicate that the gp140 is uniform in polymeric states, and high in antigenic reactivity, and is quite fittingly used as the immunogen for the research and the development of AIDS subunit vaccines or multivalent combined vaccines.

The invention relates to an oxadiazoles derivative, a preparation method and a medical application thereof, in particular to the oxadiazoles derivative of general formula 1, the preparation method, a drug composition containing the oxadiazoles derivative, and the application thereof in preparing medicines which can prevent and / or cure diseases with an IDO mediated tryptophan metabolic pathway histopathologic characteristic. The diseases comprise cancer, alzheimer disease, autoimmune disease, depression, anxiety disorder, cataract, psychologic obstacle and HIV disease. Each substituent of the general formula (1) is same with the definition in the description.

The invention relates to an oral Chinese medicine liquid for treating AIDS, and is characterized in that the medicine combination, composed of centipede, greater celandine, garter snake, pangolin, stiff silkworm, scorpion, house lizard, earthworm, safflower, salvia miltiorrhiza, angelica, rhizoma gastrodiae, radix astragali, chinese ephedra, coix seed, hemlock parsley, common burreed rhizome, rhizoma zedoariae, tambac, shizandra berry, radix puerariae, Indian bread with hostwood, tuber pinellia, achyranthes, cassia twig, immature bitter orange, airpotato yam, atractylodes rhizome, rhizoma atractylodis, broom cypress fruit, angelica dahurica, pollen and cicada slough and so on, is crushed and added with ten times of liquor for soaking for thirty days; then the medicine liquid can be taken orally so as to achieve the purpose of treating AIDS.

The present invention relates to one kind of phenolic acid compound and its preparation process and use in treating AIDS. Red sage material is treated through solvent extraction, macroporous adsorbing resin purification, conventional drying and other steps to obtain total phenolic acid. The total phenolic acid is dissolved in water via heating, chromatographic column separation and repeated purification to obtain new compound salvianolic acid N. Enzyme and cell activity experiments show that the new compound has HIV resisting activity and is hopeful in being developed into one new kind of AIDS treating medicine.

The invention provides gastrodia elata polypeptide, a preparation method and medical application of the gastrodia elata polypeptide in antibiosis and antiviral. Gastrodia elata protein is extracted, filtered and concentrated, is subjected to enzymolysis, ultrafiltration and separation, is mixed with suitable auxiliary materials according to use and application fields in proportion, and then is prepared into corresponding preparations. The gastrodia elata polypeptide is a product obtained from natural resources, and even a small amount of gastrodia elata polypeptide (10-7mol / L) has obvious biological activity. An experiment proves that the gastrodia elata polypeptide has excellent antibiosis and antiviral capabilities, has quite high killability on common pathogenic bacteria and viruses, also has the advantages of zero hemolytic activity and zero plasma coagulation activity, and can be used for preparing medicines which have an antibiosis function and can resist viral influenza, viral hepatitis, influenzavirus A sous-type H1N1, coronavirus and human acquired immunodeficiency viruses.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV:a compound of Formula Ia compound of Formula IIa compound of Formula IIIand a compound of Formula IVThese compounds are useful for the treatment of HIV and AIDS.

The present invention provides novel compounds with activity against infectious viruses. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and / or related diseases. The present invention also relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of active metabolite molecules in HIV infected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures.

The invention relates to a suspension chip detection method for simultaneously detecting hepatitis B virus, hepatitis C virus, treponema pallidum and human immunodeficiency virus pathogens. Plastic color coded microspheres with diameter of between 5.5 and 6.5 mu m are taken as vectors for a suspension chip; and the carriers are coated with monoclonal hepatitis B virus surface antibodies, HIV1, gP41 antigens, HCV NS3 antigens or treponema pallidum TP15 antigens. Through the suspension chip, the hepatitis B virus, hepatitis C virus, treponema pallidum and human immunodeficiency virus pathogens in a sample to be detected can be very conveniently and quickly detected at the same time; and the method has the advantages of accurate and reliable detection result, high specificity, small using amount of samples and high-throughput detection.

Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and / or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.